Expression of PD-L1 Is Associated with Inflammatory Microenvironment in Surgical Specimens of Non-Small Cell Lung Cancer

Expression of PD-L1 Is Associated with Inflammatory Microenvironment in Surgical Specimens of Non-Small Cell Lung Cancer

The aim of this study was to analyse the expression of PD-L1 in non-small cell lung cancer (NSCLC) and its correlation with immune microenvironment response (IMR), clinic-pathological parameters, and outcome. The sample included 76 male and 32 female patients who underwent surgical resection. The me...

Full description

Bibliographic Details
Main Authors:	Ivan Simundza, Dragan Krnic, Josko Juricic, Benjamin Benzon, Rina Simundza, Ivan Mario Stanicic, Vesna Capkun, Katarina Vukojevic, Merica Glavina Durdov
Format:	Article
Language:	English
Published:	MDPI AG 2021-08-01
Series:	Journal of Personalized Medicine
Subjects:	PD-L1 NSCLC lung surgery overall survival immunotherapy
Online Access:	https://www.mdpi.com/2075-4426/11/8/767

Similar Items

Histological Type, Cytotoxic T Cells and Macrophages in the Tumor Microenvironment Affect the PD-L1 Status of Gastric Cancer
by: Tomislav Ivanović, et al.
Published: (2023-02-01)

Expression of DENDRIN in several glomerular diseases and correlation to pathological parameters and renal failure - preliminary study
by: Maja Mizdrak, et al.
Published: (2018-11-01)

Factors That Determine Completion Rates of Biomedical Students in a PhD Programme
by: Benjamin Benzon, et al.
Published: (2020-11-01)

The landscape of immune microenvironment in lung adenocarcinoma and squamous cell carcinoma based on PD‐L1 expression and tumor‐infiltrating lymphocytes
by: Lu Chen, et al.
Published: (2019-12-01)

Atypical Response in Metastatic Non-Small Cell Lung Cancer Treated with PD-1/PD-L1 Inhibitors: Radiographic Patterns and Clinical Value of Local Therapy
by: Shanshan Jiang, et al.
Published: (2022-12-01)

Targeting the PD-1/PD-L1 axis in the treatment of lung cancer
by: Matikas Alexios, et al.
Published: (2016-03-01)

Expression of Connexins 37, 40 and 45, Pannexin 1 and Vimentin in Laryngeal Squamous Cell Carcinomas
by: Ivan Mizdrak, et al.
Published: (2023-02-01)

Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer
by: Runsen Jin, et al.
Published: (2020-08-01)

Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy
by: Kim A. Brogden, et al.
Published: (2018-02-01)

Expression Pattern of DAB Adaptor Protein 2 in Left- and Right-Side Colorectal Carcinoma
by: Ivan Šustić, et al.
Published: (2023-06-01)

PD0325901, an ERK inhibitor, enhances the efficacy of PD-1 inhibitor in non-small cell lung carcinoma
by: Min Luo, et al.
Published: (2021-10-01)

Real-World Immunotherapy Use and Effectiveness in Advanced NSCLC With Programmed Death-Ligand 1 Greater Than or Equal to 50% and Greater Than or Equal to 90%
by: Ashley Jackson, BSc, et al.
Published: (2023-12-01)

Digital Pathology and PD-L1 Testing in Non Small Cell Lung Cancer: A Workshop Record
by: Fabio Pagni, et al.
Published: (2020-07-01)

rs822336 binding to C/EBPβ and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1/PD-L1 therapy in advanced NSCLC
by: Giovanna Polcaro, et al.
Published: (2024-03-01)

Incidence risk of PD-1/PD-L1 related diarrhea in non-small cell lung cancer (NSCLC) patients: a systematic review and meta-analysis
by: Zhang C, et al.
Published: (2019-05-01)

Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors
by: Melanie Janning, et al.
Published: (2019-06-01)

Identification and validation of stromal-tumor microenvironment-based subtypes tightly associated with PD-1/PD-L1 immunotherapy and outcomes in patients with gastric cancer
by: Qianqian Ren, et al.
Published: (2020-03-01)

Clinical efficacy and safety of anti-PD-1/PD-L1 treatments in non-small cell lung cancer (NSCLC)
by: Tian Zeng, et al.
Published: (2019-12-01)

The germline HLA-A02B62 supertype is associated with a PD-L1-positive tumour immune microenvironment and poor prognosis in stage I lung cancer
by: Ruijiang Lin, et al.
Published: (2023-08-01)

PD-1+ IFN-γ+ subset of CD8+ T cell in circulation predicts response to anti–PD-1 therapy in NSCLC
by: Wenxiu Chen, et al.
Published: (2023-06-01)

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
by: Mengke Niu, et al.
Published: (2021-03-01)

Connexin Signaling in the Juxtaglomerular Apparatus (JGA) of Developing, Postnatal Healthy and Nephrotic Human Kidneys
by: Ivona Kosovic, et al.
Published: (2020-11-01)

Current Immunotherapeutic Strategies Targeting the PD-1/PD-L1 Axis in Non-Small Cell Lung Cancer with Oncogenic Driver Mutations
by: Ichidai Tanaka, et al.
Published: (2021-12-01)

Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?
by: Yaxiong Zhang, et al.
Published: (2018-12-01)

The relationship between PD-L1 expression and tumor driver gene mutations and survival in non small cell lung carcinoma
by: Kin Chan, et al.
Published: (2022-01-01)

Liver metastases and the efficacy of the PD-1 or PD-L1 inhibitors in cancer: a meta-analysis of randomized controlled trials
by: Shan Li, et al.
Published: (2020-01-01)

Role of sex and sex hormones in PD-L1 expression in NSCLC: clinical and therapeutic implications
by: Vianey Rodriguez-Lara, et al.
Published: (2023-10-01)

Erratum: Role of sex and sex hormones in PD-L1 expression in NSCLC: clinical and therapeutic implications
by: Frontiers Production Office
Published: (2024-01-01)

Radiomics combined with transcriptomics to predict response to immunotherapy from patients treated with PD-1/PD-L1 inhibitors for advanced NSCLC
by: Amine Bouhamama, et al.
Published: (2023-05-01)

Anti‐PD1 versus anti‐PD‐L1 immunotherapy in first‐line therapy for advanced non‐small cell lung cancer: A systematic review and meta‐analysis
by: Angelo Borsarelli Carvalho Brito, et al.
Published: (2021-04-01)

Association between response to anti-PD-1 treatment and blood soluble PD-L1 and IL-8 changes in patients with NSCLC
by: Ling Yi, et al.
Published: (2023-03-01)

Expression Pattern of Sonic Hedgehog, Patched and Smoothened in Clear Cell Renal Carcinoma
by: Ana Dunatov Huljev, et al.
Published: (2023-05-01)

Infection and immunity: insights and therapeutic strategies through genomic analysis of the host, pathogen, and host–pathogen interaction
by: Julia Simundza
Published: (2018-09-01)

Sex difference in the expression of PD-1 of non-small cell lung cancer
by: Yong Gu, et al.
Published: (2022-10-01)

Niclosamide, an antihelmintic drug, enhances efficacy of PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer
by: Fan Luo, et al.
Published: (2019-09-01)

PD‐L1 expressed from tumor cells promotes tumor growth and invasion in lung cancer via modulating TGF‐β1/SMAD4 expression
by: Ming‐Jenn Chen, et al.
Published: (2022-05-01)

Fascaplysin Induces Apoptosis and Ferroptosis, and Enhances Anti-PD-1 Immunotherapy in Non-Small Cell Lung Cancer (NSCLC) by Promoting PD-L1 Expression
by: Lianxiang Luo, et al.
Published: (2022-11-01)

Investigation of Programmed Cell Death-1 (PD-1) Gene Variations at Positions PD1.3 and PD1.5 in Iranian Patients with Non-small Cell Lung Cancer
by: Zahra Pirdelkhosh, et al.
Published: (2018-01-01)

Survival analysis after stereotactic ablative radiotherapy for early stage non-small cell lung cancer: a single-institution cohort study
by: Kamila Resova, et al.
Published: (2024-04-01)

Pemetrexed Enhances Membrane PD-L1 Expression and Potentiates T Cell-Mediated Cytotoxicity by Anti-PD-L1 Antibody Therapy in Non-Small-Cell Lung Cancer
by: Andrea Cavazzoni, et al.
Published: (2020-03-01)